WeightWatchers files for Chapter 11 as GLP-1s undercut the diet-program model

WW International, the company behind WeightWatchers, filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware on May 6, 2025, saying it would cut debt and keep operating ^[1][3]. The court approved the prepackaged plan on June 17, 2025, and the company exited the process on June 24, 2025 ^[2].

The filing followed years of shrinking demand for traditional diet programs as GLP-1 medicines such as Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide) spread ^[1]. WW reported a net loss of about $345.7 million for 2024 and a 5.6% year-over-year drop in subscription revenue ^[1][5]. Axios reported the company had posted six straight full-year revenue declines and three consecutive nine-digit annual losses, with 2024 revenue of $786 million — more than a billion dollars below its 2012 peak of $1.84 billion — and cumulative losses topping $700 million over three years ^[3].

The numbers behind the restructuring

WW said the reorganization would erase $1.15 billion of roughly $1.6 billion in debt ^[1]. The law firm that represented the company said the approved plan cut debt by approximately $1.15 billion, more than 70%, with lenders and noteholders receiving their pro rata share of $465 million in new senior secured term loans due 2030 plus 91% of the new common equity; existing shareholders were left with 9% ^[2]. The Chapter 11 petition estimated assets and liabilities in the $1 billion to $10 billion range ^[1]; the BBC reported total liabilities of $1.88 billion, exceeding the value of the company's assets ^[5]. WW's shares fell 40% in extended trading after the plan was announced, and had already dropped 60% since the Wall Street Journal first reported bankruptcy preparations in April ^[1].

The sources differ on what the company would look like afterward. At filing, WW said it expected the plan to be confirmed in roughly 40 days and to "emerge as a publicly traded company" ^[5], and Axios reported the company hoped to exit within 45 days or sooner ^[3]. The post-emergence announcement describes the equity split between lenders and existing shareholders but does not state whether the stock continued to trade publicly ^[2].

The GLP-1 pivot inside the numbers

WW's own results show where growth now sits. In the first quarter of 2025, subscription revenues fell 9.3%, while revenue from its clinical business — which includes weight-loss medication — rose more than 57% ^[5]. The company bought telehealth platform Sequence in 2023 to enter the obesity-drug prescribing business ^[1][3]. It had earlier rebranded as WW International in 2018 to emphasize wellness over weight loss ^[1][5], and in 2023 ended many of the in-person meetings it made famous ^[3]. Longtime investor and board member Oprah Winfrey left the board in 2024 ^[3].

Chief executive Tara Comonte, who became interim CEO in September 2024 after Sima Sistani's departure and took the permanent role in February 2025, said the plan had "the overwhelming support of our lenders" ^[3][5]. "For more than 62 years, WeightWatchers has empowered millions of members to make informed, healthy choices, staying resilient as trends have come and gone," she said ^[3][5].

Why it matters for patients

WW told members its programs, workshops and telehealth service would keep running and that there would be "no impact to members or the plans they rely on" during the reorganization ^[3][5]. Some customers might receive court notices as part of the process but were told they did not need to act ^[5].

For people who get semaglutide or tirzepatide prescriptions through a telehealth company, the case is a reminder that the businesses handling prescriptions, refills and coaching are themselves financially exposed. A restructuring changes who owns a company and what it can spend, which over time can affect pricing, program design and which services survive. WW's own figures show the shift: the shrinking part of the business is classic behavioral dieting, and the growing part is clinical care tied to drugs ^[5].

The sources do not say what WW charges for its clinical program, how many members use GLP-1 prescriptions through it, or whether insurance covers those visits. Those details are not yet known from this reporting.

What happens next

Key dates are already behind: the May 6, 2025 filing ^[1][3], plan approval on June 17, 2025, and exit from Chapter 11 on June 24, 2025 ^[2]. The new term loans mature in 2030 ^[2].